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A B S T R A C T
Objective: This study aimed to consider the estimated time to multi-resistant tuberculosis culture
conversion, and associated factors, in order to enhance evidence utilization in eastern Africa.
Methods: We systematically identified available articles on multidrug-resistant tuberculosis culture
conversion using PubMed, Scopus, Cochrane Library, Web of Science core collection, and Science Direct
databases. A random-effects model was employed using the R 3.6.1 version and Stata/se 14 software.
Results: Nine articles with a sample size of 2458 multidrug-resistant tuberculosis patients were included.
The two-month culture conversion rate was 75.4%, with a median time of 61.2 days (interquartile range:
48.6-73.8). In the included studies, favorable treatment outcomes of MDR-TB patients were seen in 75% of
the cases, while unfavorable treatment outcomes were seen in 18% (10% deaths, 7% defaulted, and 1%
treatment failure) of the cases. The independent factor for delayed sputum culture conversion was body
mass index below 18.5 kg/m2 (HR = 3.1, 95% CI: 2.0, 6.7).
Conclusion: The median time to sputum culture conversion was 61.2 days, which is a reasonably short
time. Body mass index was the identified associated factor leading to delayed culture conversion.
Therefore, there is a need for awareness of how to improve the nutritional status of multidrug-resistant
tuberculosis patients through appropriate nutritional supports.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Globally, tuberculosis (TB) was responsible for morbidities in 10
million cases and 1.5 million deaths in 2018 (WHO, 2018, 2019a).
Also, public health and health security threats continued to grow
due to the emergence of multidrug-resistant TB (MDR-TB); it
remains an impediment to eliminating TB, with 44% of patients not
successfully treated among compressed treatment recipients
(WHO, 2019a). Therefore, monitoring treatment responses is
essential to control MDR-TB and prevent the emergence ofAbbreviations: BMI, body mass index; MDR-TB, multidrug resistance tuberculo-
sis.
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chertesema@gmail.com (C.T. Leshargie), dabekle121@gmail.com (D.B. Ketema).
https://doi.org/10.1016/j.ijid.2020.06.029
1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).extensively drug-resistant (XDR-TB) strains that arise from the
mismanagement of MDR-TB individuals (WHO, 2019a,b).
Multidrug-resistant tuberculosis involves long term treat-
ment, expensive and toxic regimens, and significant risks for
drug-resistant infections (Chan et al., 2004). Shifting from the
intensive phase (usually two months) to the continuation phase
(usually four to seven months) in the treatment regime is based
on the microbiological status of patients’ sputum culture. Thus,
close monitoring is essential during treatment to assess
responses by doing cultures monthly until conversion (World
Health Organization, 2010). The status of early culture conver-
sion has been widely used as an indicator of favorable treatment
outcome and a cardinal index in monitoring treatment
response (Kurbatova et al., 2012; Holtz et al., 2006). Culture
conversion is reflected in two consecutive negative sputum
cultures taken at least 30 days apart following an initial positive
culture (WHO, 2017).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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management of patients with TB and MDR-TB therapeutically
treated in any setting and is considered as the most essential
interim efficacy indicator of treatment (Organization, 2000;
Laserson et al., 2005). Therefore, predicting the initial time to
culture conversion plays a vital role in planning and implementing
respiratory isolation (Brown et al., 2016) to determine the duration
of injectable agents and to ascertain the overall length of MDR-TB
treatment (Taylor et al., 2005).
The known risk factors influencing delayed culture conversion
are cavitary TB (Akalu et al., 2018; Bastard et al., 2019), smoking
(Velayutham et al., 2016), body mass index (BMI) (Kurbatova et al.,
2012; Velayutham et al., 2016; Magee et al., 2014), sputum smear
grade (Akalu et al., 2018), age (Holtz et al., 2006), residence
(Megerso, 2019), alcohol use (Akalu et al., 2018), type of resistance
(Akalu et al., 2018), HIV status (Bastard et al., 2019; Shibabaw et al.,
2018), and co-morbidities other than HIV (Shibabaw et al., 2018).
Culture conversion has not only been well investigated but also
has been replete with inconsistent reported findings. Hence, we
were motivated to conduct this systematic review and meta-
analysis to improve MDR-TB treatment outcomes. Therefore, the
aim of this study is to consider the evidence to estimate the pooled
time to culture conversion and its associated factors, to enhance
the utility of evidence in informing practice and policies for eastern
Africa.
2. Methods
2.1. Source of information
Systematic review and meta-analysis from databases and the
grey literature
2.2. Study settings
Eastern Africa is the part of sub-Saharan Africa including
Eastern and Horn-of-Africa nations. The Eastern Africa region hosts
seven of the world's top 30 tuberculosis burdened countries
(Ethiopia, Kenya, Mozambique, Tanzania, Zambia, Zimbabwe, and
Somalia) (WHO, 2015).
2.3. Searching strategies
Preferred reporting items for systematic review and meta-
analysis (PRISMA) guidelines were used to prepare and present this
systematic review and meta-analysis (Liberati et al., 2009). To
identify relevant articles, a comprehensive search was conducted
from November 5 to December 27, 2019, in Cochrane Library, Web
of Science (core collection), Scopus, PubMed, and Science Direct.
Published and grey literature were searched using reference lists,
conference presentations, and hand searches. Studies identified by
our search strategy were retrieved and managed using Endnote X7
(Thomson Reuters, Philadelphia, PA, USA) software. During the
search process, the authors used the following keywords and
MeSH terms: sputum culture conversion AND multidrug-resistant
pulmonary tuberculosis AND associated factors AND the 20
eastern African region countries, one by one.
2.4. Eligibility
All English language published and unpublished cohort study
design studies reporting median time to culture conversion among
adult (>18 years) MDR-TB patients in the Eastern Africa region.
Exclusion criteria: Case reports, national reports, clinical
studies, reviews, and inaccessible articles leading to an inability
to assess quality.2.5. Outcomes and definitions
Time to sputum culture conversion was the time to achieve two
consecutive negative sputum cultures taken 30 days apart after the
initial positive culture. Mono-resistant TB is resistant to one first-
line anti-TB drug only, whereas multi-resistant TB is resistant to at
least both isoniazid and rifampicin; poly-resistant TB is resistant to
more than one first-line anti-TB drug, other than both isoniazid and
rifampicin. Favorable treatment outcomes include cure and
treatment completion, while unfavorable treatment outcome
includes treatment failure, death, and/or default.
2.6. Selection of studies and data management
References were stored and managed using Endnote X7. Two
independent authors (DBK and MA) screened titles and abstracts of
a random sample of 665 eligible studies generated by our search.
Agreement on inclusion for a full-text screening of >80% between
the two independent authors was considered as good (Feldmann
et al., 2019), and the remaining references were divided among the
authors for further screening and discussion with a third author
(MAA) to find consensus as required.
2.7. Data extraction
Data extraction using a standardized MicrosoftTM Excel data
extraction tool was carried out by two independent authors (DBK and
MA) for each study, and inconsistencies were resolved by consultation
with a third author(MAA). In instancesof duplicate/multiple reports of
the same research and/or reporting the same follow-up time, we
retained the article with the largest sample size for extraction.
Treatment success (cure and treatment completion), death, lost to
follow up (LTFU), failure (default), primary authors, publication year,
studycountry,studydesign,meanage,samplesize,medianconversion
time, and two-month culture conversion status were extracted.
2.8. Quality assessment
The quality of the included studies was assessed using a modified
version of the Newcastle-Ottawa Scale (NOS) for cohort studies,
which has three main sections with eight criteria (Wells, 2001). The
first section scored, based on one to four stars, focuses on the
selection. The second section of the tool considers the comparability
of the study based on design, with a possibility of one star to be
gained. The third and last section is concerned with outcomes with
the possibility of three stars. Also, a quality appraisal of included
studies was evaluated independently by two authors (CTL and DBK);
any discrepancies were resolved bya third author (MAA). The studies
that reached at least five stars on NOS criteria were considered high-
quality studies and were included in this review.
2.9. Data processing and analysis
A MicrosoftTM Excel spreadsheet form was used to present the
extracted data from the primary studies, and further analysis was
done by R Version 3.6.1 and Stata/se 14. Heterogeneity was assessed
by computing p-values of Higgins's I2 test statistics and Q-statistics
among reported median time of culture conversion. The Higgins's I2
statistic measures the difference between sample quartile estima-
tion, which is due to heterogeneity due to random error rather than
to sampling error. In this case, the pooled effect was estimated with
a random-effects meta-analysis model. Subgroup analysis was
computed to identify the possible sources of heterogeneity by
considering sample size, country, and publicationyear. Median time
was presented in quartile estimation, and the associated factors of
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a 95% level of significance.
3. Results
A total of 665 sputum culture conversion studies were extracted
from the web-based databases. We excluded 466 articles due to
duplication, and the remaining 199 studies were assessed for
eligibility. In the next phase, 163 articles were removed after
reading the title and abstract. Finally, nine of 36 articles were found
eligible, accessible, and were included in the final analysis after
reading the full text (Fig. 1).
3.1. Description of included studies
As described in Table 1, nine acceptable quality observational
cohort articles with a total sample size of 2458 from five countries
were included. The smallest sample size was 25 in Tanzania
(Ndusilo et al., 2015), while the largest sample size was 634 in
Mozambique (multicenter) (Bastard et al., 2019). Regarding the
time to sputum culture conversion, the shortest was 34 days in
Ethiopia (Megerso, 2019), while the longest was 90 days in Rwanda
(Muvunyi et al., 2019).Fig. 1. Flow chart of selecting articles for systemat3.2. Type of resistance and treatment outcomes
This meta-analysis found 45.6% mono resistant and 54.4%
poly/multi-resistant TB cases (Figs. 2 and 3). As we have found
from primary study reports, only baseline sputum smear grades
before treatment were included. The status of sputum smear
grade was 37% grade 1+, 42.1% grade 2+ and 21.9% grade 3+.
Favorable treatment outcomes of MDR-TB patients in the
included studies were seen in 75% (95 CI: 61, 81) of cases, while
18% had unfavorable treatment outcomes (10% died, 7% defaulted
and1% treatment failure) (Fig. 4). Three quarters (75.4%) of the
MDR-TB patients had culture conversion in the second month
(Fig. 5).
3.3. Time to sputum culture conversion among MDR-TB patients in
eastern Africa
The median time to sputum culture conversion was 61.2 days
(IQR: 48.6–73.8) (I2 = 99.2%, p-value <0.001). The pooled median
time of culture conversion in this meta-analysis showed high
heterogeneity, according to the Higgins I2 test (I2 = 99.2, p < 0.001).
Thus, we carried out a subgroup analysis to identify the sources of
heterogeneity (Table 2).ic review and meta-analysis in eastern Africa.
Table 1
Descriptive summary of sputum culture conversion among MDR-TB patients in eastern Africa.
Authors Publication
(yr)







Favorable Unfavorable Mono Multi
Mpagama et al.
(2013)
2013 Tanzania Retrospective NA 70 60 (30,90) 85 77 16 46 54
Ndusilo et al.
(2015)
2015 Tanzania Retrospective 37 25 45 (45,90) 84 72 28 84 16
Huerga et al.
(2017)
2016 Kenya Retrospective 29 125 60 (60,90) 74 66 20 NA NA
Akalu et al. (2018) 2018 Ethiopia Retrospective 29.5 392 65 (60,700 56 58 19 51 49
Shibabaw et al.
(2018)
2018 Ethiopia Retrospective 30 235 72 (44,123) NA 62 24 10 60





Prospective NA 325 42 (28,68) NA NA 4 28 72
Bastard et al.
(2019)
2019 Mozanbique Retrospective 35 634 88 (57,138) 76.8 73 28 59 41
Muvunyi et al.
(2019)
2019 Rwanda Retrospective 40 173 90 (30,210) NA 87 12 19 81
Fig. 2. Mono drug-resistant patients from systematic review and meta-analysis in eastern Africa.
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In this study, the associated factors identified were cavitation,
residence, cigarette smoking, alcohol use, body mass index (BMI),
sputum smear grading, and type of resistance, HIV status, and co-
morbidities other than HIV. However, only BMI was reported
across three of the included studies and found to be statistically
significant.
Mono-resistant TB with an odds ratio of 0.73 (95% CI: 0.42,
1.28), cigarette smoking with an odds ratio of 1.08 (95% CI: 0.61,
1.90), negative HIV status 0.63 (95% CI: 0.45, 0.86), co-morbidities
other than HIV were reported in single studies, so we were not
able to pool to generate the effect size of the factors on culture
conversion.
The associations between cavitation, alcohol use, and urban
residence with time to culture conversion were calculated from
two studies. Thus, none of the three factors were found
significantly associated with the time to culture conversion with
a pooled ratio of 2.32 (95% CI: 0.96, 3.63), 1.11 (95% CI: 0.72, 1.51),
and 1.15 (95% CI: 0.91, 1.41) respectively.The association between BMI and time to culture conversion
was calculated from three studies. The median time to culture
conversion was three times more likely to be delayed among
patients whose BMI was below 18.5 kg/m2 compared to patients
whose BMI was above 18.5 kg/m2 (HR = 0.32, 95% CI: 0.15, 0.5) at a
given follow-up time.
4. Discussion
In the Eastern African setting, there is a high burden of drug-
resistant tuberculosis. This review aimed to further legitimize time
to sputum culture conversion as a useful interim efficacy index and
prognostic tool for monitoring treatment response and predicting
treatment success in TB patients. Three-quarters of MDR-TB
patients on treatment achieved favorable treatment outcomes
(cure and treatment completed). In contrast, the proportion of
unfavorable treatment outcome in this study was 18% which is
consistent with the studies conducted in Nigeria (15%) (Oladimeji
et al., 2014) and Botswana 17% (Hafkin et al., 2013) but lower than
studies reported in South Africa (31.6%) (Seung et al., 2009) and
Fig. 3. Poly/multidrug-resistant patients from systematic review and meta-analysis in eastern Africa.
Fig. 4. Treatment outcomes of MDR-TB patients from systematic review and meta-analysis in eastern Africa.
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be due to sample size, study design, study period, or study setting –
we used the pooled effect of five countries with different settings;
also, other studies did consider unknown treatment outcomes.
The rate of culture conversion in the second month was 76%,
and the median time was 61.2 days. The median time to sputum
culture conversion is consistent with studies in Peru, 59 days
(Tierney et al., 2014), South Korea, 56 days (Kim et al., 2016),
Indonesia, 60 days (Putri et al., 2014), the Dominican Republic, 60days (Rodriguez et al., 2013), Latvia, 60 days (Holtz et al., 2006) and
Georgia, 68 days (Magee et al., 2014). Our finding showed a shorter
duration than the studies conducted in Delhi, 91.3 days (Velayu-
tham et al., 2016), and London, 91 days (Rieu et al., 2015). This
variation could be explained by the sample size, study settings,
methodology, and the time when they are conducted.
We have found low BMI as a significant factor for delayed
sputum culture conversion. In our study, the likelihood of time to
sputum culture conversion is prolonged in those with low BMI (i.e.,
Fig. 5. Rate of second-month culture conversion among MDR-TB patients from systematic review and meta-analysis in eastern Africa.
Table 2
Subgroup analysis of sputum culture conversion among MDR-TB patients.
Variables Characteristics No articles included Sample size Median time (IQR) p-value
Country of eastern Africa Ethiopia 4 1491 52.9 (35.3, 70.6) <0.001
Tanzania 2 95 53.7 (39.2,68.22) <0.001
Kenya 2 450 50.9 (33.3,68.6) <0.001
Sample size Below median (263) 5 1864 (52.5,76.5) <0.001
Above median (263) 4 594 57.2 (33.4,81) <0.001
Publication Prior 2017 3 220 59 (54.3,63.6) <0.001
Post 2017 6 2238 64.3 (45.8,82.7) <0.001
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(Magee et al., 2014), Delhi (Velayutham et al., 2016), Indonesia
(Rodriguez et al., 2013), South Korea (Park et al., 2016), and five
other low-income countries (Kurbatova et al., 2012). This variation
could be due to BMI being a measure of the level of malnutrition. In
patients with tuberculosis, malnutrition leads to a reduction in
appetite, nutrient and micronutrient mal-absorption, and altered
metabolism leading to wasting. Thus, malnourished tuberculosis
patients have delayed recovery and higher mortality rates than
well-nourished patients (Gupta et al., 2009) due to the suppression
of immunity, leading to increased susceptibility to infectious and
non-infectious diseases.
In general, early sputum culture conversion is an important
index in monitoring treatment outcomes by increasing patients’
comfort by shortening the intensive phase duration of injectable
drugs and decreasing transmission of the disease when precau-
tions are not adequate. Moreover, improved nutritional status and
supplementation of patients will represent a novel approach for
the rapid recovery of MDR-TB patients.4.1. Limitation of the study
Only English language reports were considered in this study,
which may have restricted the inclusion of some relevant
eastern African studies. Some of the studies included in this
review had a relatively small sample size, which may reduce
generalizability. This meta-analysis represented only studies
reported from five of 22 countries due to the unavailability of
other studies.
5. Conclusion
The median time to sputum culture conversion was 61.2 days,
which is a reasonably short time. Low BMI was the identified
associated factor leading to delayed culture conversion. Therefore,
there is a need for awareness on how to improve the nutritional
status of multidrug-resistant tuberculosis patients through appro-
priate dietary supports.




Availability of data and material
All available data are within the paper.
Competing interests
The authors declare that they have no competing interests.
Funding
The authors received no specific funding for this work.
Author contributions
MAA: conception of the research protocol, study design,
literature review, data extraction, data analysis, interpretation,
and drafting of the manuscript.
MA: study design, literature review, data extraction, data
analysis, interpretation, and manuscript review.
CTL: data extraction, data analysis, quality assessment, inter-
pretation, and manuscript review.
PMP: quality assessment and critically reviewed and validated
the manuscript.
DBK: study design and contribute to data extraction, quality
assessment, data analysis, and manuscript review. All authors have
read and approved the manuscript.
Acknowledgments
Authors of primary studies.
References
Akalu TY, Muchie KF, Gelaye KA. Time to sputum culture conversion and its
determinants among multidrug resistant tuberculosis patients at public
hospitals of the Amhara Regional State: a multicenter retrospective follow
up study. PLoS ONE 2018;13(6):e0199320.
Bastard M, Sanchez-Padilla E, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T,
et al.What is the best cultureconversionprognostic marker for patientstreated for
multidrug-resistant tuberculosis?. Int J Tuberc Lung Dis 2019;23(10):1060–7.
Brown EG, Dooley D, Backer H. Drug-resistant tuberculosis: national collaborating
centre for infectious diseases. 2016.
Chan ED, Laurel V, Strand MJ, Chan JF, Huynh M-LN, Goble M, et al. Treatment and
outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J
Respir Crit Care Med 2004;169(10):1103–9.
Feldmann M, Ullrich C, Bataillard C, Knirsch W, Gosteli-Peter MA, Latal B, et al.
Neurocognitive outcome of school-aged children with congenital heart disease
who underwent cardiopulmonary bypass surgery: a systematic review
protocol. Syst Rev 2019;8(1):236.
Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and nutrition.
Lung India: Off Organ Indian Chest Soc 2009;26(1):9.
HafkinJMC, NewcombC,LowenthaE. Impactof thehumanimmunodeficiencyvirus on
early multidrug-resistant tuberculosis treatment outcomes in Botswana. 2013.
Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time
to sputum culture conversion in multidrug-resistant tuberculosis: predictors
and relationship to treatment outcome. Ann Intern Med 2006;144(9):650–9.
Huerga H, Bastard M, Kamene M, Wanjala S, Arnold A, Oucho N, et al. Outcomes
from the first multidrug-resistant tuberculosis programme in Kenya. Int J
Tuberc Lung Dis 2017;21(3):314–9.
Isaakidis PCH, Varghese B, Montaldo C, Da Silva E. Ambulatory multidrug resistant
tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum
setting in Mumbai, India. PLoS ONE 2011;.
Kim J, Kwak N, Lee HY, Kim TS, Kim C-K, Han SK, et al. effect of drug resistance on
negative conversion of sputum culture in patients with pulmonary tuberculosis.
Int J Infect Dis 2016;42:64–8.Kurbatova E, Gammino V, Bayona J, Becerra M, Danilovitz M, Falzon D, et al.
Predictors of sputum culture conversion among patients treated for multidrug-
resistant tuberculosis. Int J Tuberc Lung Dis 2012;16(10):1335–43.
Laserson KF, Thorpe L, Leimane V, Weyer K, Mitnick C, Riekstina V, et al. Speaking
the same language: treatment outcome definitions for multidrug-resistant
tuberculosis. Int J Tuberc Lung Dis 2005;9(6):640–5.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The
PRISMA statement for reporting systematic reviews and meta-analyses of
studies that evaluate health care interventions: explanation and elaboration.
PLoS Med 2009;6(7):e1000100.
Magee MJ, Kempker RR, Kipiani M, Tukvadze N, Howards PP, Narayan KV, et al.
Diabetes mellitus, smoking status, and rate of sputum culture conversion in
patients with multidrug-resistant tuberculosis: a cohort study from the country
of Georgia. PLoS ONE 2014;9(4):e94890.
Megerso A. Time to culture conversion and its determinants among multidrug
resistant tuberculosis patients on second line treatment: a survival analysis.
2019.
Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, et al.
Diagnosis and interim treatment outcomes from the first cohort of multidrug-
resistant tuberculosis patients in Tanzania. PLoS ONE 2013;8(5):e62034.
Muvunyi CM, Ngabonziza JCS, Uwimana I, Harelimana JDD, Mucyo Y, Sebatunzi OR,
et al. Highly successful treatment outcome of multidrug-resistant and genetic
diversity of multidrug-resistant Mycobacterium tuberculosis strains in Rwanda.
Trop Med Int Health 2019;.
Ndusilo ND, Heysell SK, Mpagama SG, Gratz J, Segesela FH, Pazia SJ, et al.
Improvement in plasma drug activity during the early treatment interval among
Tanzanian patients with multidrug-resistant tuberculosis. PLoS ONE 2015;10
(3):e0122769.
Oladimeji OIP, Obasanya OJ, Eltayeb O, Khogali M. Intensive-phase treatment
outcomes among hospitalized multidrug-resistant tuberculosis patients:
results from a Nationwide cohort in Nigeria. PLoS ONE 2014;.
Organization WH. Guidelines for establishing DOTS-Plus pilot projects for the
management of multidrug-resistant tuberculosis (MDR-TB). World Health
Organization; 2000.
Park H-O, Kim S-H, Moon S-H, Byun J-H, Kim J-W, Lee C-E, et al. Association between
body mass index and sputum culture conversion among South Korean patients
with multidrug resistant tuberculosis in a tuberculosis referral hospital. Infect
Chemother 2016;48(4):317–23.
Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, Agustin H, et al. Body mass
index predictive of sputum culture conversion among MDR-TB patients in
Indonesia. Int J Tuberc Lung Dis 2014;18(5):564–70.
Rieu R, Chang C, Collin SM, Fazekas J, Dassanaike S, Abbara A, et al. time to detection
in liquid culture of sputum in pulmonary MDR-TB does not predict culture
conversion for early discharge. J Antimicrob Chemother 2015;71(3):803–6.
Rodriguez M, Monedero I, Caminero J, Encarnación M, Dominguez Y, Acosta I, et al.
Successful management of multidrug-resistant tuberculosis under programme
conditions in the Dominican Republic. Int J Tuberc Lung Dis 2013;17(4):520–5.
Seung KJOD, Keshavjee S, Furin JJ, Farmer PE, Hind S. Early outcomes of MDR-TB
treatment in a high HIV-prevalence setting in southern Africa. PLoS ONE 2009;.
Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, Alam M, et al. Culture conversion
at 6 months in patients receiving delamanid-containing regimens for the
treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2019;.
Shibabaw A, Gelaw B, Wang S-H, Tessema B. Time to sputum smear and culture
conversions in multidrug resistant tuberculosis at University of Gondar
Hospital, Northwest Ethiopia. PLoS ONE 2018;13(6):e0198080.
Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States.
Recommendations from the American Thoracic Society, CDC, and the Infectious
Diseases Society of America. Recommendations and reports: Morbidity and
mortality weekly report. MMWR 2005;54(RR-12):1–81.
Tierney DB, Franke MF, Becerra MC, Viru FAA, Bonilla CA, Sánchez E, et al. Time to
culture conversion and regimen composition in multidrug-resistant tubercu-
losis treatment. PLoS ONE 2014;9(9):e108035.
Velayutham B, Nair D, Kannan T, Padmapriyadarsini C, Sachdeva K, Bency J, et al.
Factors associated with sputum culture conversion in multidrug-resistant
pulmonary tuberculosis. Int J Tuberc Lung Dis 2016;20(12):1671–6.
Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non
randomised studies in meta-analyses. 2001 https://www.ohrica/programs/
clinical_epidemiology/oxford asp.
WHO. Use of high burden country lists for TB by WHO in the post-2015 era:
summary 2016. Available from: https://www.who.int/tb/publications/global_-
report/high_tb_burdencountrylists2016-2020summary.pdf?ua=1
WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care.
2017 Available from: https://apps.who.int/iris/bitstream/handle/10665/
255052/9789241550000-eng.pdf.
WHO. The top 10 causes of death May 24. 2018 Available from: https://www.who.
int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
WHO. Key facts on tuberculosis. October 2019 Available from: https://www.who.
int/news-room/fact-sheets/detail/tuberculosis.
WHO. Global tuberculosis report. 2019 Available from: https://reliefweb.int/report/
world/global-tuberculosis-report.
World Health Organization. Stop TB initiative. Treatment of tuberculosis: guide-
lines. World Health Organization; 2010.
